Centro Hospitalar Lisboa Norte, EPE- Hospital de Santa Maria

Lisbon 1649-035

0 studies enrolling now · 11 studies all time

What they study most

ATTR-PN, Advanced Cholangiocarcinoma, Breast Cancer, Carcinoma, Hepatocellular, Dravet Syndrome, Dravet Syndrome (DS), Epilepsy, FGFR2 Gene Mutation, Head and Neck Cancer, Lennox-Gastaut Syndrome, Lennox-Gastaut Syndrome (LGS), Liver Cirrhosis, Biliary

Studies at this site

• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of Soticlestat in Adults and Children With Rare Epilepsies — Stopped early
• Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) — Completed
• Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma — Completed
• A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma — Completed
• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations — Stopped early
• Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence — Stopped early
• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis — Stopped early
• Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis — Completed
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma — Completed
• A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies — Completed